Antibody Industry Trends

Despite comprising the largest family of druggable membrane proteins, only three G protein-coupled receptor (GPCR)-targeting antibodies have been approved. The human genome has more than 800 GPCRs, which regulate various critical physiological processes, but many GPCRs are expressed poorly, or have unknown ligands and unclear signaling pathways.

In 2025, 21 novel monoclonal antibody (mAb) drugs were approved for the first time worldwide. These approvals represent an expansion of both antibody modality and therapeutic focus, with developments in bispecifics, ADCs, long-acting formulations, and first-in-class mechanisms.

Biointron’s Q4 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in October, November, and December. This quarter, 5 novel monoclonal antibody drugs have been approved by the US, UK, and China.

Recent studies in antibody formulation highlight challenges in achieving high-concentration, stable, and patient-friendly formulations. These efforts include possible solutions in improving self-administration, global distribution without cold-chain reliance, and reducing healthcare system burdens.

Antibody discovery has traditionally relied on methods like hybridoma technology and phage display, but these approaches face increasing limitations, including low throughput, disrupted antibody chain pairing, and time-consuming workflows.

Psoriasis affects more than 100 million people around the world.The fieldof monoclonal antibody (mAb) therapeuticshas evolved from broad immunosuppressants to engineered biologics targeting key cytokine nodes in psoriatic inflammation, namely TNF-α, IL-17, and IL-23. This trend ha

Over the past few months, the biotech landscape saw venture funding of antibody companies with significant seed-to-Series D rounds across a wide range of disease areas. A key trend emerging is the diversification of antibody modalities, spanning bispecifics, antibody-drug conjugates (ADCs), radioiso

As viral threats continue to emerge and evolve, a new generation of antibody formats, derived from birds, camelids, and sharks, is gaining traction as a promising alternative for rapid, scalable, and resilient immunotherapies.A recent review by Basabrain & Alandijany (2025) describes how avian i

In recent years, the development of nanoparticles has expanded into a large range of clinical applications, including antibody conjugation and incorporation.

Over the past year, a surge of billion-dollar alliances has drawn attention to an increasingly dynamic Asian landscape, where novel antibodies, bispecifics, and antibody-drug conjugates (ADCs) are fast becoming the region’s calling cards.

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s disease represent an escalating global health challenge, driven by an aging population and the lack of effective disease-modifying therapies.

​The therapeutic potential of antibodies in cancer immunotherapy can be affected by their capacity to modulate T cell states within the tumor microenvironment (TME).